IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Alethia Young - Cantor Fitzgerald - Analyst : So to start off, maybe can you just discuss IDEAYA's vision and how it originated? In general, what has the Company accomplished to date?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Awesome. Can you talk a little bit about your synthetic lethality platform, and how you go into selecting programs? I feel like it is a relatively well-known concept, but just talk a little bit about it, and from your perspective, synthetic lethality. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 30, 2021 / 3:20PM, IDYA.OQ - IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay. And so what in the platform helps you, enables you to go past HRD?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Got it. Is your strategy generally that -- I know some of these people have worked on in the past. Is your strategy to work better on things that are targets that have popped up from SL, or is it more like to find really novel things or is it a combination of both?

Question: Alethia Young - Cantor Fitzgerald - Analyst : And so talk a little bit about the pharma collaborations between Glaxo and Pfizer? You probably have over $3 billion in potential milestones. Are these your two beachhead collaborations, or are you looking to do more partnership? Just how do you think about that versus development in-house?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Awesome. Let's move on talk about 397 and the MAT2A, MTAP. First maybe, I know a competitor, Agios, had mixed data in it, and so I guess I wanted to talk about how you differentiate 397, just your general perspective on development in that space before we get into your Phase 1 study.

Question: Alethia Young - Cantor Fitzgerald - Analyst : Yes. So let's go and talk about your Phase 1, which I think you're going to have some tumor data at the end of the quarter -- or in the fourth quarter. We are not in the fourth quarter yet. So just talk about the design of the Phase 1 study first.

Question: Alethia Young - Cantor Fitzgerald - Analyst : So you haven't had trouble with getting biopsies with COVID or anything?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay. And then I guess you're saying so it's all comer so you're not necessarily selecting for MTAP deletions but they do exist in, what, like 15% or so of solid tumors. Is that right?

Question: Alethia Young - Cantor Fitzgerald - Analyst : And so going forward, would you focus more in lung or would you focus in other ones that have higher prevalence MTAP deletions?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay so when you go into escalation, you will go into it with a combo and mono?

Question: Alethia Young - Cantor Fitzgerald - Analyst : And can you just talk about the 60% plasma SAM reduction as a clinical threshold, how you derive that and how we should think about it?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Yes. I was going to say, isn't that a little surprising?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay. Let's move on to PARG, your PARG inhibitor, okay, just maybe talk about the target first and then we'll talk about a little preclinical data. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 30, 2021 / 3:20PM, IDYA.OQ - IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Question: Alethia Young - Cantor Fitzgerald - Analyst : Yes that's interesting. So it seems like -- I think you're first-in-class in this, right? Because I guess I'm wondering how people missed this and how your technology or your discovery technology picked it up.

Question: Alethia Young - Cantor Fitzgerald - Analyst : So wait, is this something that would be potentially used with PARP, or is it something that's more competitive to PARP?

Question: Alethia Young - Cantor Fitzgerald - Analyst : I was going to ask about biomarkers, but it sounds like that work is underway. Is that fair?

Question: Alethia Young - Cantor Fitzgerald - Analyst : And remind me again when you're going to select the development candidate.

Question: Alethia Young - Cantor Fitzgerald - Analyst : Oh, okay, so soon.

Question: Alethia Young - Cantor Fitzgerald - Analyst : Are there any kind of other updates in preclinical that we should be aware of that are informing the space that you've presented?

Question: Alethia Young - Cantor Fitzgerald - Analyst : So being able to I guess differentiate target on the helicase inhibitor versus the other, I mean, is it something that's just difficult to do, or is it just like people made the active decision not to do it?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay, that's -- so you are the only one targeting helicase?

Question: Alethia Young - Cantor Fitzgerald - Analyst : You are ahead. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 30, 2021 / 3:20PM, IDYA.OQ - IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Question: Alethia Young - Cantor Fitzgerald - Analyst : That's fair. Can you just talk a little bit about what you saw with IDE196 and the Phase 1/2 update?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Okay. Anything else that we should be thinking about or talking about with your story?

Question: Alethia Young - Cantor Fitzgerald - Analyst : Awesome. Thank you very much, guys, for the update. We look forward to the data coming at the end of the year.